EP3443097A4 - Vaccin universel pour maladies virales - Google Patents

Vaccin universel pour maladies virales Download PDF

Info

Publication number
EP3443097A4
EP3443097A4 EP17782018.0A EP17782018A EP3443097A4 EP 3443097 A4 EP3443097 A4 EP 3443097A4 EP 17782018 A EP17782018 A EP 17782018A EP 3443097 A4 EP3443097 A4 EP 3443097A4
Authority
EP
European Patent Office
Prior art keywords
viral diseases
universal vaccine
vaccine
universal
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17782018.0A
Other languages
German (de)
English (en)
Other versions
EP3443097A1 (fr
Inventor
Rodolfo César BELLINZONI
Emmanuel Gérard Etienne RÉGULIER
Ana ROMO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogenesis Bago Hong Kong Ltd
Biogenesis Bago Uruguay SA
Original Assignee
Biogenesis Bago Hong Kong Ltd
Biogenesis Bago Uruguay SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogenesis Bago Hong Kong Ltd, Biogenesis Bago Uruguay SA filed Critical Biogenesis Bago Hong Kong Ltd
Publication of EP3443097A1 publication Critical patent/EP3443097A1/fr
Publication of EP3443097A4 publication Critical patent/EP3443097A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP17782018.0A 2016-04-11 2017-04-07 Vaccin universel pour maladies virales Withdrawn EP3443097A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662320852P 2016-04-11 2016-04-11
PCT/IB2017/052030 WO2017178945A1 (fr) 2016-04-11 2017-04-07 Vaccin universel pour maladies virales

Publications (2)

Publication Number Publication Date
EP3443097A1 EP3443097A1 (fr) 2019-02-20
EP3443097A4 true EP3443097A4 (fr) 2020-04-22

Family

ID=60041433

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17782018.0A Withdrawn EP3443097A4 (fr) 2016-04-11 2017-04-07 Vaccin universel pour maladies virales

Country Status (9)

Country Link
US (2) US10940196B2 (fr)
EP (1) EP3443097A4 (fr)
KR (1) KR20180132742A (fr)
CN (1) CN109196104B (fr)
AR (1) AR108014A1 (fr)
BR (1) BR112018070634A2 (fr)
TW (1) TWI763662B (fr)
UY (1) UY37198A (fr)
WO (1) WO2017178945A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2809219C1 (ru) * 2023-05-11 2023-12-07 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГТУ "ВНИИЗЖ") Вакцина против ящура генотипа SAT-1/NWZ культуральная инактивированная сорбированная

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3909970A1 (fr) * 2020-05-14 2021-11-17 Consejo Superior De Investigaciones Científicas Vaccins peptidiques pour la prévention de la fièvre aphteuse
CN111744000B (zh) * 2020-07-14 2021-03-23 中国农业科学院兰州兽医研究所 免疫抑制功能降低的口蹄疫重组病毒及其制备方法与应用
CN111978380A (zh) * 2020-09-02 2020-11-24 天康生物股份有限公司 野生型气肿疽梭菌细胞毒素a及其制备方法、应用和疫苗
CN114748617B (zh) * 2022-03-24 2024-04-16 华南农业大学 一种大口黑鲈虹彩病毒的亚单位疫苗及其制备方法和应用
CN114874338B (zh) * 2022-05-18 2024-04-12 华中农业大学 一种口蹄疫病毒纳米颗粒及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078732A1 (fr) * 2001-02-15 2002-10-10 The Registrar, Indian Institute Of Science Nouvelle formulation de vaccin constituee d'un virus inactive de vaccin adn
WO2005121330A2 (fr) * 2004-06-03 2005-12-22 Goldgene Llc Proteines chimeres isolees de lumazine synthase modifiee
CN102168088A (zh) * 2010-12-23 2011-08-31 中国农业科学院兰州兽医研究所 T细胞免疫原基因ti及其在口蹄疫蛋白亚单位疫苗和灭活疫苗中的应用
WO2014191903A1 (fr) * 2013-05-27 2014-12-04 Inmunova S.A. Chimères de lumazine synthase de brucella et sous-unité bêta des toxines ab5

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408434A (zh) * 2002-09-16 2003-04-09 复旦大学 抗家畜口蹄疫的多肽和dna联合疫苗及其制备方法
KR20210149203A (ko) 2009-11-02 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 구제역 바이러스(ｆｍｄｖ) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신
CN101948811B (zh) * 2010-08-18 2013-01-09 中国农业科学院兰州兽医研究所 用反向遗传操作拓展口蹄疫疫苗株抗原谱及疫苗制备方法
BR112015023651A2 (pt) * 2013-03-15 2017-10-24 Novavax Inc expressão aumentada de proteínas de picornavírus
CN105056227B (zh) * 2015-07-21 2017-12-29 复旦大学 一种抗口蹄疫病毒的类病毒粒子vlp疫苗及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078732A1 (fr) * 2001-02-15 2002-10-10 The Registrar, Indian Institute Of Science Nouvelle formulation de vaccin constituee d'un virus inactive de vaccin adn
WO2005121330A2 (fr) * 2004-06-03 2005-12-22 Goldgene Llc Proteines chimeres isolees de lumazine synthase modifiee
CN102168088A (zh) * 2010-12-23 2011-08-31 中国农业科学院兰州兽医研究所 T细胞免疫原基因ti及其在口蹄疫蛋白亚单位疫苗和灭活疫苗中的应用
CN102168088B (zh) * 2010-12-23 2012-12-26 中国农业科学院兰州兽医研究所 T细胞免疫原基因ti及其在口蹄疫蛋白亚单位疫苗和灭活疫苗中的应用
WO2014191903A1 (fr) * 2013-05-27 2014-12-04 Inmunova S.A. Chimères de lumazine synthase de brucella et sous-unité bêta des toxines ab5

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BERINSTEIN A ET AL: "Avridine and LPS from Brucella ovis: Effect on the memory induced by foot-and-mouth disease virus vaccination in mice", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 11, no. 13, 1 October 1993 (1993-10-01), pages 1295 - 1301, XP023710483, ISSN: 0264-410X, [retrieved on 19931001], DOI: 10.1016/0264-410X(93)90098-I *
DATABASE WPI Week 201168, Derwent World Patents Index; AN 2011-M14574 *
LAPLAGNE D A ET AL: "Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides", PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS, JOHN WILEY & SONS, INC, US, vol. 57, no. 4, 18 August 2004 (2004-08-18), pages 820 - 828, XP002478641, ISSN: 0887-3585, [retrieved on 20040818], DOI: 10.1002/PROT.20248 *
PETER LAING ET AL: "The 'Co-Delivery' Approach to Liposomal Vaccines: Application to the Development of influenza-A and hepatitis-B Vaccine Candidates", JOURNAL OF LIPOSOME RESEARCH., vol. 16, no. 3, 9 January 2006 (2006-01-09), US, pages 229 - 235, XP055477541, ISSN: 0898-2104, DOI: 10.1080/08982100600880432 *
SCIUTTO E ET AL: "Brucella spp. lumazine synthase: a novel antigen delivery system", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 21, 15 April 2005 (2005-04-15), pages 2784 - 2790, XP027652091, ISSN: 0264-410X, [retrieved on 20050415] *
See also references of WO2017178945A1 *
ZAKHARTCHOUK A N ET AL: "Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 35, 15 August 2005 (2005-08-15), pages 4385 - 4391, XP027651863, ISSN: 0264-410X, [retrieved on 20050815] *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2810132C1 (ru) * 2023-04-04 2023-12-22 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Вакцина против ящура генотипа SAT-1/X из штамма "SAT-1/Нигерия/2015" культуральная инактивированная сорбированная
RU2809219C1 (ru) * 2023-05-11 2023-12-07 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГТУ "ВНИИЗЖ") Вакцина против ящура генотипа SAT-1/NWZ культуральная инактивированная сорбированная

Also Published As

Publication number Publication date
WO2017178945A1 (fr) 2017-10-19
AR108014A1 (es) 2018-07-11
CN109196104B (zh) 2023-01-31
US20190142926A1 (en) 2019-05-16
TWI763662B (zh) 2022-05-11
EP3443097A1 (fr) 2019-02-20
US10940196B2 (en) 2021-03-09
TW201740973A (zh) 2017-12-01
US20210187096A1 (en) 2021-06-24
KR20180132742A (ko) 2018-12-12
BR112018070634A2 (pt) 2019-02-05
CN109196104A (zh) 2019-01-11
UY37198A (es) 2017-11-30

Similar Documents

Publication Publication Date Title
EP3551193A4 (fr) Vaccins à acide nucléique contre des virus respiratoires
EP3538146A4 (fr) Vaccin antigrippal
EP3713601A4 (fr) Vaccins contre le virus d'epstein-barr
EP3528821A4 (fr) Vaccin contre le cytomégalovirus humain
EP3365009A4 (fr) Vaccin contre le virus de l'herpès simplex
EP3364983A4 (fr) Vaccins contre les virus respiratoires
EP3324979A4 (fr) Vaccins contre une maladie infectieuse
EP3364982A4 (fr) Vaccins contre les maladies sexuellement transmissibles
EP3364981A4 (fr) Vaccin contre le cytomégalovirus humain
EP3365008A4 (fr) Vaccin contre le virus respiratoire syncytial
EP3134131A4 (fr) Vaccins à base d'acide nucléique
EP3233878A4 (fr) Phosphoramidates pour le traitement du virus de l'hépatite b
EP3095798A4 (fr) Vaccin thérapeutique renforçant l'immunité contre le papillomavirus humain et des maladies apparentées
EP3102190A4 (fr) Nouvelles formulations pharmaceutiques
EP3125576A4 (fr) Haut-parleur universel
EP3094652A4 (fr) Nouveaux vaccins contre le vph et maladies liées au vph
EP3443097A4 (fr) Vaccin universel pour maladies virales
EP3194595A4 (fr) Segments d'arn viral utilisés en tant qu'agents immunomodulateurs et composants de vaccin
EP3315599A4 (fr) Vaccin antitumoral par voie orale
EP3362052A4 (fr) Procédés pour préparer des préparations pour thérapies ciblant le tractus gastro-intestinal
ZA201808121B (en) Therapeutic hpv vaccine combinations
EP3107614A4 (fr) Système jetable multidose
EP3158830A4 (fr) Système de chauffage pour pochettes à usage unique
EP3168490A4 (fr) Joint homocinétique tripode
EP3400007A4 (fr) Virus de type orthomyxovirus du tilapia

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200325

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/135 20060101ALI20200319BHEP

Ipc: C07K 7/08 20060101ALI20200319BHEP

Ipc: C07K 14/09 20060101ALI20200319BHEP

Ipc: C12N 15/62 20060101AFI20200319BHEP

Ipc: A61P 31/14 20060101ALI20200319BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201218

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231107